Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NT5E | P21589 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16651618 | 0.85 | CYP1A2 (0.56) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651113 | 0.84 | CYP1A2 (0.55) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651040 | 0.83 | RXFP1 (0.57) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651221 | 0.83 | CYP1A2 (0.48) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651243 | 0.81 | RORC (0.55) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12749518 | 0.81 | CYP1A2 (0.51) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651474 | 0.80 | CYP1A2 (0.46) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651515 | 0.79 | CYP1A2 (0.54) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL16651840 | 0.78 | RORC (0.51) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL15648578 | 0.78 | RORC (0.55) | RORCCYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3057422-B1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-10201546-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-29 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| EP-3057422-A1 | QUINOLINYL MODULATORS OF ROR(GAMMA)T | Janssen Pharmaceutica NV (BE) | 2016-08-24 | — | — | EP | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015057626-A1 | QUINOLINYL MODULATORS OF RORyT | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885CYP1A2 577/4885CYP2D6 417/4885 |
| US-10201546-B2 | Quinolinyl modulators of RORγt | RORC, RORB, RORA | RORC 1/4885CYP1A2 404/4885CYP2D6 454/4885 |
| US-20170182056-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | RORC 1/4885CYP1A2 577/4885CYP2D6 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.